| Year |
Title |
Altmetric |
| 2022
|
Associations between geography, decision-making style, and interest in cancer clinical trial participation.
Cancer.
128:3977-3984.
2022
|
|
| 2022
|
Emerging perspectives on growth factor metabolic relationships in the ovarian cancer ascites environment.
Seminars in Cancer Biology.
86:709-719.
2022
|
|
| 2022
|
Genomic profiling in low grade serous ovarian cancer: Identification of novel markers for disease diagnosis and therapy.
Gynecologic Oncology.
167:306-313.
2022
|
|
| 2022
|
Ineligible, Unaware, or Uninterested? Associations between Underrepresented Patient Populations and Retention in the Pathway to Cancer Clinical Trial Enrollment.
Jco Oncology Practice.
18:E1854-E1865.
2022
|
|
| 2022
|
PVT1 is a stress-responsive lncRNA that drives ovarian cancer metastasis and chemoresistance.
Life Science Alliance.
5.
2022
|
|
| 2022
|
Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup
2022
|
|
| 2022
|
Reciprocal SOX2 regulation by SMAD1-SMAD3 is critical for anoikis resistance and metastasis in cancer.
Cell Reports.
40.
2022
|
|
| 2022
|
Circulating Tregs Accumulate in Omental Tumors and Acquire Adipose-Resident Features.
Cancer Immunology Research.
10:641-655.
2022
|
|
| 2022
|
Metabolic Alterations and WNT Signaling Impact Immune Response in HGSOC.
Clinical Cancer Research.
28:1433-1445.
2022
|
|
| 2022
|
High-intermediate risk endometrial cancer: moving toward a molecularly based risk assessment profile.
International Journal of Clinical Oncology.
27:323-331.
2022
|
|
| 2022
|
Response to anti-DKK1 therapy in uterine carcinosarcoma: A case report.
Gynecologic Oncology Reports.
39.
2022
|
|
| 2022
|
Homologous Recombination Deficiency: Concepts, Definitions, and Assays
2022
|
|
| 2022
|
International gynecologic cancer society (IGCS) 2021 meeting report.
Gynecologic Oncology.
164:208-211.
2022
|
|
| 2022
|
Sequential modulation of the Wnt/β-catenin signaling pathway enhances tumor-intrinsic MHC I expression and tumor clearance.
Gynecologic Oncology.
164:170-180.
2022
|
|
| 2022
|
Utilization of Poly(ADP-Ribose) Polymerase Inhibitors in Ovarian Cancer: A Retrospective Cohort Study of US Healthcare Claims Data.
Advances in Therapy.
39:328-345.
2022
|
|
| 2021
|
Gynecologic oncology patients are ready for telemedicine in routine care: Results from a pre-COVID survey.
Gynecologic Oncology Reports.
38.
2021
|
|
| 2021
|
Identifying a molecular profile to predict the risk of recurrence in high-intermediate risk endometrial cancer.
Cancer Medicine.
10:8238-8250.
2021
|
|
| 2021
|
Systematic Next Generation Sequencing is feasible in clinical practice and identifies opportunities for targeted therapy in women with uterine cancer: Results from a prospective cohort study.
Gynecologic Oncology.
163:85-92.
2021
|
|
| 2021
|
Strategies in overcoming homologous recombination proficiency and PARP inhibitor resistance.
Molecular Cancer Therapeutics.
20:1542-1549.
2021
|
|
| 2021
|
Understanding the effect of mechanical forces on ovarian cancer progression.
Gynecologic Oncology.
162:154-162.
2021
|
|
| 2021
|
Utilizing an interim futility analysis of the OVAL study (VB-111-701/GOG 3018) for potential reduction of risk: A phase III, double blind, randomized controlled trial of ofranergene obadenovec (VB-111) and weekly paclitaxel in patients with platinum resistant ovarian cancer.
Gynecologic Oncology.
161:496-501.
2021
|
|
| 2021
|
Assessing preclinical research models for immunotherapy for gynecologic malignancies.
Cancers.
13.
2021
|
|
| 2021
|
TGFβ signaling networks in ovarian cancer progression and plasticity.
Clinical and Experimental Metastasis.
38:139-161.
2021
|
|
| 2021
|
Endometrial cancer: A society of gynecologic oncology evidence-based review and recommendations.
Gynecologic Oncology.
160:817-826.
2021
|
|
| 2021
|
Endometrial cancer: A society of gynecologic oncology evidence-based review and recommendations, part II.
Gynecologic Oncology.
160:827-834.
2021
|
|
| 2021
|
Neutralization of TGFβ improves tumor immunity and reduces tumor progression in ovarian carcinoma.
Molecular Cancer Therapeutics.
20:602-611.
2021
|
|
| 2021
|
Class I histone deacetylase inhibition promotes CD8 T cell activation in ovarian cancer.
Cancer Medicine.
10:709-717.
2021
|
|
| 2021
|
Manipulating the Wnt/β-catenin signaling pathway to promote anti-tumor immune infiltration into the TME to sensitize ovarian cancer to ICB therapy.
Gynecologic Oncology.
160:285-294.
2021
|
|
| 2021
|
Ovarian cancer: new strategies and emerging targets for the treatment of patients with advanced disease.
Cancer Biology and Therapy.
22:89-105.
2021
|
|
| 2021
|
Utilization of a 3-D tissue engineered model to investigate the effects of perfusion on gynecologic cancer biology.
Journal of Tissue Engineering.
12.
2021
|
|
| 2020
|
Obesity diminishes response to PD-1-based immunotherapies in renal cancer.
Journal for ImmunoTherapy of Cancer.
8.
2020
|
|
| 2020
|
Corrigendum to ‘Wnt signaling modulator DKK1 as an immunotherapeutic target in ovarian cancer’ [Gynecologic Oncology 157 (2020) 765–774] (Gynecologic Oncology (2020) 157(3) (765–774), (S0090825820302262), (10.1016/j.ygyno.2020.03.010)).
Gynecologic Oncology.
159:295.
2020
|
|
| 2020
|
The anti-DKK1 antibody DKN-01 as an immunomodulatory combination partner for the treatment of cancer.
Expert Opinion on Investigational Drugs.
29:639-644.
2020
|
|
| 2020
|
Ofranergene obadenovec (VB-111) in platinum-resistant ovarian cancer; favorable response rates in a phase I/II study are associated with an immunotherapeutic effect.
Gynecologic Oncology.
157:578-584.
2020
|
|
| 2020
|
Wnt signaling modulator DKK1 as an immunotherapeutic target in ovarian cancer.
Gynecologic Oncology.
157:765-774.
2020
|
|
| 2020
|
A Ketogenic Diet Is Acceptable in Women with Ovarian and Endometrial Cancer and Has No Adverse Effects on Blood Lipids: A Randomized, Controlled Trial
2020
|
|
| 2020
|
Decision analysis for secondline maintenance treatment of platinum sensitive recurrent ovarian cancer: A review.
International Journal of Gynecological Cancer.
30:684-694.
2020
|
|
| 2020
|
Inhibiting WNT ligand production for improved immune recognition in the Ovarian tumor microenvironment.
Cancers.
12.
2020
|
|
| 2020
|
EMR 20006-012: A phase II randomized double-blind placebo controlled trial comparing the combination of pimasertib (MEK inhibitor) with SAR245409 (PI3K inhibitor) to pimasertib alone in patients with previously treated unresectable borderline or low grade ovarian cancer.
Gynecologic Oncology.
156:301-307.
2020
|
|
| 2020
|
Large, Non-Cavity Distorting Intramural Leiomyomas Decrease Leukemia Inhibitory Factor in the Secretory Phase Endometrium.
Reproductive Sciences.
27:569-574.
2020
|
|
| 2020
|
Inhibition of the Wnt/β-catenin pathway enhances antitumor immunity in ovarian cancer.
Therapeutic Advances in Medical Oncology.
12.
2020
|
|
| 2019
|
Biomarkers in ovarian cancer: To be or not to be.
Cancer.
125:4563-4572.
2019
|
|
| 2019
|
Histone deacetylase inhibition promotes intratumoral CD8+ T-cell responses, sensitizing murine breast tumors to anti-PD1
2019
|
|
| 2019
|
Extending the platinum-free interval: The impact of omitting 2nd line platinum chemotherapy in intermediate platinum-sensitive ovarian cancer.
Gynecologic Oncology.
155:201-206.
2019
|
|
| 2019
|
Neutrophilia and mortality in women with uterine carcinosarcoma.
International Journal of Gynecological Cancer.
29:1258-1263.
2019
|
|
| 2019
|
Advancing drug development in gynecologic malignancies.
Clinical Cancer Research.
25:4874-4880.
2019
|
|
| 2019
|
Checkpoint inhibitors in ovarian cancer: A review of preclinical data.
Gynecologic Oncology Reports.
29:48-54.
2019
|
|
| 2019
|
A review of the role of wnt in cancer immunomodulation.
Cancers.
11.
2019
|
|
| 2019
|
Review: Targeting the transforming growth factor-beta pathway in ovarian cancer.
Cancers.
11.
2019
|
|
| 2019
|
The expression of MHC class II molecules on murine breast tumors delays T-cell exhaustion, expands the T-cell repertoire, and slows tumor growth
2019
|
|
| 2019
|
Overcoming immune suppression with epigenetic modification in ovarian cancer
2019
|
|
| 2019
|
Humanistic and economic impact of subcutaneous versus intravenous administration of oncology biologics.
Future Oncology.
15:3267-3281.
2019
|
|
| 2018
|
The antitumor effects of entinostat in ovarian cancer require adaptive immunity.
Cancer.
124:4657-4666.
2018
|
|
| 2018
|
Revisiting entinostat as an immune-potentiating adjuvant.
Oncotarget.
9:37278-37279.
2018
|
|
| 2018
|
Systemic Treatment of Metastatic/Recurrent Uterine Leiomyosarcoma: A Changing Paradigm
2018
|
|
| 2018
|
FTY720 enhances the anti-tumor activity of carboplatin and tamoxifen in a patient-derived xenograft model of ovarian cancer.
Cancer Letters.
436:75-86.
2018
|
|
| 2018
|
Disparities in receipt of follow-up care instructions among female adult cancer survivors: Results from a national survey.
Gynecologic Oncology.
150:494-500.
2018
|
|
| 2018
|
Endometrial cancer: Molecular markers and management of advanced stage disease.
Gynecologic Oncology.
150:569-580.
2018
|
|
| 2018
|
Favorable effects of a ketogenic diet on physical function, perceived energy, and food cravings in women with ovarian or endometrial cancer: A randomized, controlled trial.
Nutrients.
10.
2018
|
|
| 2018
|
A ketogenic diet reduces central obesity and serum insulin in women with ovarian or endometrial cancer
2018
|
|
| 2018
|
Molecular response to neoadjuvant chemotherapy in high-grade serous ovarian carcinoma.
Molecular Cancer Research.
16:813-824.
2018
|
|
| 2018
|
Correction: Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer [Oncotarget., 7, (2016) (86803-86815)] 10.18632/oncotarget.13466.
Oncotarget.
9:19459-19459.
2018
|
|
| 2018
|
Histone methyltransferase ezh2: A therapeutic target for ovarian cancer.
Molecular Cancer Therapeutics.
17:591-602.
2018
|
|
| 2018
|
Insulin-like growth factor 2: a poor prognostic biomarker linked to racial disparity in women with uterine carcinosarcoma.
Cancer Medicine.
7:616-625.
2018
|
|
| 2017
|
Epigenetic therapy for the treatment of epithelial ovarian cancer: A clinical review.
Gynecologic Oncology Reports.
20:81-86.
2017
|
|
| 2017
|
B7-H3-targeted 212Pb radioimmunotherapy of ovarian cancer in preclinical models.
Nuclear Medicine and Biology.
47:23-30.
2017
|
|
| 2017
|
Epigenetic modifiers upregulate MHC II and impede ovarian cancer tumor growth.
Oncotarget.
8:44159-44170.
2017
|
|
| 2017
|
Implementation and utilization of the molecular tumor board to guide precision medicine.
Oncotarget.
8:57845-57854.
2017
|
|
| 2017
|
Uterine carcinosarcomas: Clinical, histopathologic and immunohistochemical characteristics
2017
|
|
| 2016
|
Ovarian cancer and the immune system — The role of targeted therapies.
Gynecologic Oncology.
142:349-356.
2016
|
|
| 2016
|
The tumor-associated glycosyltransferase ST6Gal-I regulates stem cell transcription factors and confers a cancer stem cell phenotype.
Cancer Research.
76:3978-3988.
2016
|
|
| 2016
|
Targeting the Wnt/β-catenin pathway in primary ovarian cancer with the porcupine inhibitor WNT974.
Laboratory Investigation.
96:249-259.
2016
|
|
| 2016
|
Metabolic risk factors and mechanisms of disease in epithelial ovarian cancer: A review.
Gynecologic Oncology.
143:674-683.
2016
|
|
| 2016
|
Niclosamide and its analogs are potent inhibitors of Wnt/ß- catenin, mTOR and STAT3 signaling in ovarian cancer.
Oncotarget.
7:86803-86815.
2016
|
|
| 2015
|
Niclosamide analogs for treatment of ovarian cancer.
International Journal of Gynecological Cancer.
25:1377-1385.
2015
|
|
| 2015
|
PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: A cost-effectiveness analysis.
Gynecologic Oncology.
139:59-62.
2015
|
|
| 2014
|
Ovarian cancer stem cells: Can targeted therapy lead to improved progression-free survival?.
World Journal of Stem Cells.
6:441-447.
2014
|
|
| 2014
|
Multi-targeted therapy of cancer by niclosamide: A new application for an old drug.
Cancer Letters.
349:8-14.
2014
|
|
| 2014
|
Effect of niclosamide on basal-like breast cancers.
Molecular Cancer Therapeutics.
13:800-811.
2014
|
|
| 2014
|
Inhibition of Wnt/β-catenin pathway by niclosamide: A therapeutic target for ovarian cancer.
Gynecologic Oncology.
134:112-120.
2014
|
|
| 2014
|
Radical surgical cytoreduction in the treatment of ovarian carcinosarcoma.
Gynecologic Oncology.
133:234-237.
2014
|
|
| 2013
|
The Wnt/β-catenin pathway in ovarian cancer: A review.
Gynecologic Oncology.
131:772-779.
2013
|
|
| 2013
|
Folate and folate receptor alpha antagonists mechanism of action in ovarian cancer.
Gynecologic Oncology.
131:493-498.
2013
|
|
| 2012
|
Failure to rescue as a source of variation in hospital mortality for ovarian cancer.
Journal of Clinical Oncology.
30:3976-3982.
2012
|
|
| 2011
|
Uterine carcinosarcoma.
Current Opinion in Oncology.
23:531-536.
2011
|
|
| 2010
|
Long-term outcome and natural history of uterine adenosarcomas.
Gynecologic Oncology.
119:305-308.
2010
|
|
| 2010
|
Fertility preservation in ovarian cancer.
Clinical Practice.
7:257-267.
2010
|
|
| 2010
|
Co-expression of GPR30 and ERβ and their association with disease progression in uterine carcinosarcoma.
American Journal of Obstetrics and Gynecology.
203:242.e1-242.e5.
2010
|
|
| 2009
|
Extragenital adenosarcoma: A case report, review of the literature, and management discussion.
Gynecologic Oncology.
115:472-475.
2009
|
|
| 2009
|
Tissue microarray analysis of hormonal signaling pathways in uterine carcinosarcoma.
American Journal of Obstetrics and Gynecology.
200:457.e1-457.e5.
2009
|
|
